These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 24053274)

  • 1. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
    Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
    Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
    Brüggemann RJ; Antonius T; Heijst Av; Hoogerbrugge PM; Burger DM; Warris A
    Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of voriconazole in children.
    Chen J; Chan C; Colantonio D; Seto W
    Ther Drug Monit; 2012 Feb; 34(1):77-84. PubMed ID: 22210097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.
    Bartelink IH; Wolfs T; Jonker M; de Waal M; Egberts TC; Ververs TT; Boelens JJ; Bierings M
    Antimicrob Agents Chemother; 2013 Jan; 57(1):235-40. PubMed ID: 23114771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
    Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
    Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of voriconazole and posaconazole.
    Hussaini T; Rüping MJ; Farowski F; Vehreschild JJ; Cornely OA
    Pharmacotherapy; 2011 Feb; 31(2):214-25. PubMed ID: 21275497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole in clinical practice.
    Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
    J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.
    Boyd NK; Zoellner CL; Swancutt MA; Bhavan KP
    Antimicrob Agents Chemother; 2012 Nov; 56(11):6001-2. PubMed ID: 22890768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and clinical use of voriconazole.
    Thompson GR; Lewis JS
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.
    Aperis G; Mylonakis E
    Expert Opin Investig Drugs; 2006 Jun; 15(6):579-602. PubMed ID: 16732713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.
    Maschmeyer G; Haas A
    Future Microbiol; 2006 Dec; 1(4):365-85. PubMed ID: 17661629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
    Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
    Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole.
    Med Lett Drugs Ther; 2002 Jul; 44(1135):63-5. PubMed ID: 12138377
    [No Abstract]   [Full Text] [Related]  

  • 15. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
    van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
    Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
    Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG
    J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacology of the antifungals used in the treatment of aspergillosis].
    Azanza JR; Sádaba B; Gómez-Guíu A
    Rev Iberoam Micol; 2014; 31(4):255-61. PubMed ID: 25442382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isavuconazole: Case Report and Pharmacokinetic Considerations.
    Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
    Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.
    George D; Miniter P; Andriole VT
    Antimicrob Agents Chemother; 1996 Jan; 40(1):86-91. PubMed ID: 8787885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.